LNTH - Why Lantheus Stock Is Soaring Today
Shares of Lantheus Holdings (NASDAQ: LNTH) were soaring 17.1% as of 11:01 a.m. EDT on Thursday. The big jump came after the company announced that the Food and Drug Administration had approved Pylarify, an imaging agent used to identify prostate cancer.
Today's significant gain for the life sciences stock underscores how optimistic investors are about the market potential for Pylarify. It's the first imaging agent to win FDA approval that's targeted to the prostate-specific membrane antigen (PSMA) for use in positron emission tomography.
Image source: Getty Images.
For further details see:
Why Lantheus Stock Is Soaring Today